Royal Bank Of Canada Sigilon Therapeutics, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.48 - $0.86 $96 - $173	202 Added 1.12%	18,203 $9,000
Q2 2022 Aug 15, 2022	SELL	$0.74 - $1.64 $1,208 - $2,678	-1,633 Reduced 8.32%	18,001 $15,000
Q1 2022 May 16, 2022	SELL	$1.24 - $3.03 $2,359 - $5,766	-1,903 Reduced 8.84%	19,634 $28,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $50,211 - $119,302	19,462 Added 937.93%	21,537 $60,000
Q3 2021 Nov 15, 2021	BUY	$4.42 - $10.61 $6,121 - $14,694	1,385 Added 200.72%	2,075 $12,000
Q2 2021 Aug 16, 2021	BUY	$9.15 - $20.17 $6,313 - $13,917	690 New	690 $7,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.